A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.

A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.

Zhitong FinanceJul 4 14:42

Altimmune to Participate at Leerink Partners Therapeutics Forum

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one

GlobeNewswireJul 2 19:30

3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics

Yahoo FinanceJun 30 18:53

If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy

Yahoo FinanceJun 29 23:34

Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.

Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.

BenzingaJun 27 22:34

Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'

Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'

BenzingaJun 27 22:26